1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsSmall Business Innovation Research (SBIR) Program Phase I is sponsored by National Institutes of Health (NIH) National Eye Institute (NEI). Supports small businesses in developing innovative technologies to advance eye health, including AI applications in optometry.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Small Business | National Eye Institute The NEI Small Business Innovative Research (SBIR) (R43/R44) and Small Business Technology Transfer Research (STTR) (R41/R42) programs provide early-stage capital for innovative small U.S. companies for the purpose of engaging in federal Research & Development (R&D) that has a strong potential for commercialization.
Both the SBIR and STTR programs are divided into three phases, however, only the first two received federal funds. Phase I is the Feasibility and Proof of Concept stage, which establishes the technical merit, feasibility, and commercial potential of the proposed Research and Development (R&D) project and also determines the quality of performance of the small business.
Phase II is the Research and Development stage, which continues the R&D work initiated in Phase I and brings the project to an advanced level, approaching commercialization. Phase III is the Commercialization stage, where the small business pursues commercialization objectives to bring the product to market with non SBIR/STTR funds.
Key elements of the SBIR and STTR programs are as follows: Allows for a wide range of topics and innovative projects with strong science/technology, and high commercialization potential Provides funding for three phases depending on performance: Phase I Feasibility grant: 6 months to 2 years and $295,924 (total costs) Phase II R&D grant: 2 years and $1,972,828 (total costs) Phase IIB Competing Renewal R&D grant for projects that need extraordinary time & effort in the R&D stage to develop such projects: 2 years and $1,972,828 (total costs) Offers distinct technical assistance programs to SBIR Phase I and Phase II awardees which include a Niche Assessment Program and a Commercialization Acceleration Program Gives access to the NIH Regulatory Assistance Program, which aids in the procurement of consultants knowledgeable in the federal regulatory process necessary for the approval of new drugs and devices and helps grantees bring innovative vision and eye care products to the marketplace more efficiently Learn more about NEI's small business grant programs Retina, Glaucoma, and Low Vision Anterior Segment (Cornea, Lens, and Dry Eye) Strabismus, Amblyopia, Visual Processing (SAVP) Watch videos about Small Business Program Last updated: February 13, 2026
According to the current listing, eligibility includes: Small businesses meeting SBA size standards. Confirm the full requirements in the official notice before applying.
The current listing shows $150,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
This listing does not include a published deadline, but it is an annual program. Check the official notice for the current cycle's exact dates.
Small Business Innovation Research (SBIR) Program Phase I is funded by National Institutes of Health (NIH) National Eye Institute (NEI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article